The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia (Q31491869)

2 July 2017

0 references

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia (English)

1 reference

2 July 2017

0 references

1 reference

1 reference

S R David

1

1 reference

2 July 2017

C C Taylor

series ordinal

2

1 reference

2 July 2017

B J Kinon

series ordinal

3

1 reference

2 July 2017

A Breier

series ordinal

4

1 reference

2 July 2017

publication date

1 September 2000

1 reference

2 July 2017

published in

Clinical Therapeutics

1 reference

2 July 2017

volume

22

1 reference

2 July 2017

issue

9

1 reference

2 July 2017

page(s)

1085-1096

1 reference

Clozapine does not elevate serum prolactin levels in healthy men

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Clozapine: plasma levels and prolactin response

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Effect of clozapine on human serum prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Prolactin levels and adverse events in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Prolactogenic effects of risperidone in male patients--a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

A study of serum prolactin levels in schizophrenia: comparison of males and females

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Risperidone and associated amenorrhea: a report of 5 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

Effects of the menstrual cycle on dependent variables in mood disorder research

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980086-7

7 January 2021

10.1016/S0149-2918(00)80086-7

Identifiers

DOI

1 reference

2 July 2017

1 reference